Crescent Biopharma, Inc.
CBIO Nasdaq
SEC CIK 1253689
Follow Crescent Biopharma
Weekly email: filings, results
Revenue, last quarter
$3.1M
Net income
−$37.7M
−53.3% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$26.9M
−53.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $10.8M | $153.9K |
| FY24 | - | $37.9K |
| FY23 | $10K | $36.9K |
| FY22 | $75K | −$46.7M |
| FY21 | $1.2M | −$63.4M |
| FY20 | $10.2M | −$51M |
| FY19 | - | −$57.9M |
| FY18 | - | −$48.3M |
| FY17 | - | −$33.3M |
| FY16 | $18.5K | −$31.8M |
| FY15 | $20.1M | −$12.8M |
| FY14 | $15M | −$11.1M |
| FY13 | $4M | −$10.6M |
| FY12 | $15.3M | $3.7M |
| FY11 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −1407.5% | 1.4% |
| FY24 | - | - |
| FY23 | −392752.9% | 369% |
| FY22 | −63204.4% | −62251.7% |
| FY21 | −5470.7% | −5469% |
| FY20 | −506.8% | −502.1% |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | −172505.3% | −171945.1% |
| FY15 | −63.7% | −63.6% |
| FY14 | −74.1% | −74% |
| FY13 | −265.7% | −265.6% |
| FY12 | 23.8% | 24% |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$72.5M |
| FY24 | −$31.1M |
| FY23 | −$34.9M |
| FY22 | −$46.5M |
| FY21 | −$57.5M |
| FY20 | −$39.3M |
| FY19 | −$52.1M |
| FY18 | −$43.5M |
| FY17 | −$30.1M |
| FY16 | −$30.4M |
| FY15 | −$8.5M |
| FY14 | −$4.5M |
| FY13 | −$15.6M |
| FY12 | −$10.8M |
| FY11 | - |
- Crescent Biopharma
- Healthcare median
Show the numbers
| Year | Crescent Biopharma | Healthcare median |
|---|---|---|
| FY25 | 1.4% | −30.6% |
| FY24 | - | −47% |
| FY23 | 369% | −58% |
| FY22 | −62251.7% | −80.4% |
| FY21 | −5469% | −71.8% |
| FY20 | −502.1% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | −171945.1% | −36% |
| FY15 | −63.6% | −37.8% |
| FY14 | −74% | −35.5% |
| FY13 | −265.6% | −37.1% |
| FY12 | 24% | −29.1% |
| FY11 | - | −27.9% |